Hims & Hers Health, Inc. $HIMS Shares Sold by Strong Tower Advisory Services

Strong Tower Advisory Services cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 1.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,222 shares of the company’s stock after selling 384 shares during the quarter. Strong Tower Advisory Services’ holdings in Hims & Hers Health were worth $1,008,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of HIMS. Wealth Enhancement Advisory Services LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at approximately $213,000. UMB Bank n.a. lifted its holdings in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares during the period. Farther Finance Advisors LLC lifted its holdings in Hims & Hers Health by 12.9% in the first quarter. Farther Finance Advisors LLC now owns 8,122 shares of the company’s stock valued at $252,000 after acquiring an additional 930 shares during the period. GAMMA Investing LLC lifted its holdings in Hims & Hers Health by 128.5% in the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company’s stock valued at $152,000 after acquiring an additional 2,892 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in Hims & Hers Health by 23.1% in the first quarter. Handelsbanken Fonder AB now owns 41,100 shares of the company’s stock valued at $1,215,000 after acquiring an additional 7,700 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, insider Irene Becklund sold 8,410 shares of the company’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares in the company, valued at $71,609. This represents a 85.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $58.79, for a total value of $155,029.23. Following the completion of the sale, the insider owned 163,767 shares of the company’s stock, valued at approximately $9,627,861.93. The trade was a 1.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,622,741 shares of company stock worth $83,695,469 over the last quarter. Corporate insiders own 13.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Saturday, September 27th. Finally, Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Stock Down 7.3%

Shares of HIMS opened at $53.98 on Friday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The stock has a 50 day moving average price of $50.86 and a 200 day moving average price of $47.90. The stock has a market capitalization of $12.20 billion, a price-to-earnings ratio of 67.48, a PEG ratio of 3.93 and a beta of 2.25. Hims & Hers Health, Inc. has a one year low of $17.36 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.